{
    "clinical_study": {
        "@rank": "31657", 
        "arm_group": [
            {
                "arm_group_label": "Neoadjuvant Bevacizumab", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Active Control", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This randomized, open-label study will evaluate the efficacy and safety of neoadjuvant\n      Avastin (bevacizumab) in patients with initially unresectable, FIGO stage IIIC/IV ovarian,\n      tubal or peritoneal cancer. Patients will be randomized to receive 8 cycles of carboplatin\n      plus paclitaxel with or without Avastin 15 mg/kg intravenously every 3 weeks in Cycles 1 to\n      3 before surgery. All patients will receive Avastin 15 mg/kg intravenously every 3 weeks for\n      Cycles 6 to 26. Anticipated time on study treatment is until disease progression or\n      unacceptable toxicity occurs, for up to a maximum of 26 cycles."
        }, 
        "brief_title": "A Study of Avastin (Bevacizumab) in Neoadjuvant Therapy in Patients With FIGO Stage IIIC/IV Ovarian, Tubal or Peritoneal Cancer, Initially Unresectable", 
        "completion_date": {
            "#text": "February 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Ovarian Cancer", 
        "condition_browse": {
            "mesh_term": "Ovarian Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult female patients, >/= 18 years of age\n\n          -  Histologically confirmed and documented high risk stage IIIC/IV epithelial ovarian\n             carcinoma, fallopian tube carcinoma or primary peritoneal carcinoma\n\n          -  Patients are required to be deemed by a surgeon experienced in the management of\n             ovarian cancer not to be eligible for primary complete debulking surgery during a\n             laparoscopic procedure\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2\n\n          -  Life expectancy >/= 3 months\n\n          -  Eligible for carboplatin and paclitaxel chemotherapy in accordance with local\n             standards\n\n          -  Patient should be beneficiary of healthcare coverage under the social security system\n\n        Exclusion Criteria:\n\n          -  Non-epithelial ovarian cancer, ovarian tumour with low malignant potential, or\n             mucinous and clear cell ovarian cancer\n\n          -  Evidence of abdominal free air not explained by paracentesis or recent surgical\n             procedure\n\n          -  Previous systemic therapy for ovarian cancer\n\n          -  Previous exposure to mouse CA-125 antibody\n\n          -  Current or recent treatment (within 28 days prior to Day 1, Cycle 1) with another\n             investigational drug or previous participation in this study\n\n          -  Current or recent (within 10 days prior to first study drug dose) chronic daily\n             treatment with aspirin (>325 mg/day)\n\n          -  Planned intraperitoneal cytotoxic chemotherapy\n\n          -  Inadequate bone marrow, liver or renal function\n\n          -  History of myocardial infarction, unstable angina, stroke or ischemic attack within 6\n             months prior to Day 1, Cycle 1\n\n          -  Uncontrolled hypertension\n\n          -  Clinically significant (i.e. active) cardiovascular disease (e.g. NYHA Class II or\n             greater congestive heart failure, aortic aneurism)\n\n          -  Pre-existing peripheral neuropathy >/= CTC Grade 2\n\n          -  Known hypersensitivity to bevacizumab or its excipients, Chinese hamster ovary cell\n             products or other recombinant humanized antibodies or to any planned chemotherapy\n\n          -  Pregnant or lactating females\n\n          -  History of other clinically active malignancy within 5 years of enrolment, except for\n             tumours with a negligible risk for metastasis or death, such as adequately controlled\n             basal-cell or squamous-cell carcinoma of the skin or carcinoma in situ of the cervix\n             or breast"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "99", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 28, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01739218", 
            "org_study_id": "ML28337", 
            "secondary_id": "2012-001144-22"
        }, 
        "intervention": [
            {
                "arm_group_label": "Neoadjuvant Bevacizumab", 
                "description": "15 mg/kg iv every 3 weeks, Day 1 of Cycles 1-3", 
                "intervention_name": "bevacizumab [Avastin]", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Neoadjuvant Bevacizumab", 
                    "Active Control"
                ], 
                "description": "AUC 5 mg/mL/min iv every 3 weeks, Day 1 of Cycles 1-8", 
                "intervention_name": "Carboplatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Neoadjuvant Bevacizumab", 
                    "Active Control"
                ], 
                "description": "175 mg/m2 iv every 3 weeks, Day 1 of Cycles 1-4, and 175 mg/m2 every 3 weeks or 80 mg/m2 weekly Cycles 5-8", 
                "intervention_name": "paclitaxel", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Neoadjuvant Bevacizumab", 
                    "Active Control"
                ], 
                "description": "15 mg/kg iv every 3 weeks, Day 1 of Cycles 6-26", 
                "intervention_name": "bevacizumab [Avastin]", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Bevacizumab", 
                "Carboplatin", 
                "Paclitaxel"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 26, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Amiens", 
                        "country": "France", 
                        "zip": "80054"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Besancon", 
                        "country": "France", 
                        "zip": "25030"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bordeaux", 
                        "country": "France", 
                        "zip": "33076"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Caen", 
                        "country": "France", 
                        "zip": "14076"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Clermont Ferrand", 
                        "country": "France", 
                        "zip": "63011"
                    }
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lille", 
                        "country": "France", 
                        "zip": "59020"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Marseille", 
                        "country": "France", 
                        "zip": "13273"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montpellier", 
                        "country": "France", 
                        "zip": "34298"
                    }
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nice", 
                        "country": "France", 
                        "zip": "06189"
                    }
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75231"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75908"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75970"
                    }
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St Cloud", 
                        "country": "France", 
                        "zip": "92210"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toulouse", 
                        "country": "France", 
                        "zip": "31059"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Villejuif", 
                        "country": "France", 
                        "zip": "94805"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Open-label, Phase II Study Assessing the Efficacy and the Safety of Bevacizumab in Neoadjuvant Therapy in Patients With FIGO Stage IIIC/IV Ovarian, Tubal or Peritoneal Adenocarcinoma, Initially Unresectable.", 
        "overall_contact": {
            "email": "global.rochegenentechtrials@roche.com", 
            "last_name": "Reference Study ID Number: ML28337 www.roche.com/about_roche/roche_worldwide.htm", 
            "phone": "888-662-6728 (U.S. Only)"
        }, 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: ANSM - Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Complete resection rate after interval debulking surgery (IDS), defined as complete removal of all macroscopic residual tumour at IDS (Completeness of Cytoreduction Score = 0)", 
            "safety_issue": "No", 
            "time_frame": "approximately 4 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01739218"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Objective response rate before IDS (neoadjuvant phase), assessed according to RECIST v1.1 criteria and/or CA-125 levels)", 
                "safety_issue": "No", 
                "time_frame": "approximately 4 years"
            }, 
            {
                "measure": "Objective response rate after all courses of treatment (16 months following IDS)", 
                "safety_issue": "No", 
                "time_frame": "approximately 4 years"
            }, 
            {
                "measure": "Progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "approximately 4 years"
            }, 
            {
                "measure": "Safety: Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "approximately 4 years"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}